Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
68.30 USD   +4.42%
10/02Safety Of Intravitreal Pegcetacoplan In Geographic Atrophy : 24-Month Results from the Phase 3 OAKS and DERBY Trials
PU
10/02Efficacy Of Intravitreal Pegcetacoplan In Geographic Atrophy : 24-Month Results from the Phase 3 OAKS and DERBY Trials
PU
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year Outcomes from the Randomized Phase 3 OAKS and DERBY Trials
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
59.3(c) 61.76(c) 63(c) 65.41(c) 68.3(c) Last
842 286 1 036 388 801 061 2 368 756 2 101 584 Volume
+1.68% +4.15% +2.01% +3.83% +4.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 79,1 M - -
Net income 2022 -627 M - -
Net cash position 2022 400 M - -
P/E ratio 2022 -11,5x
Yield 2022 -
Sales 2023 271 M - -
Net income 2023 -523 M - -
Net cash position 2023 84,2 M - -
P/E ratio 2023 -14,6x
Yield 2023 -
Capitalization 7 504 M 7 504 M -
EV / Sales 2022 89,8x
EV / Sales 2023 27,4x
Nbr of Employees 476
Free-Float 84,5%
More Financials
Company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative... 
Sector
Pharmaceuticals
Calendar
10/02 | 09:12amPresentation
More about the company
Ratings of Apellis Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about APELLIS PHARMACEUTICALS, INC.
10/02Safety Of Intravitreal Pegcetacoplan : 24-Month Results from the Phase 3 OAKS and DERBY Tr..
PU
10/02Efficacy Of Intravitreal Pegcetacopl : 24-Month Results from the Phase 3 OAKS and DERBY Tr..
PU
09/30Aao 2022 : Treatment of Geographic Atrophy Secondary to AMD with Pegcetacoplan: Two-Year O..
PU
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacopla..
GL
09/30Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treat..
CI
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/30Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studi..
GL
09/16Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities Global..
CI
09/12Insider Sell: Apellis Pharmaceuticals
MT
09/12Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global H..
GL
09/12Wedbush Raises Price Target on Apellis Pharmaceuticals to $67 From $55, Sees Increased ..
MT
09/08Insider Sell: Apellis Pharmaceuticals
MT
09/08Stifel Nicolaus Adjusts Price Target on Apellis Pharmaceuticals to $65 From $60, Keeps ..
MT
09/07Insider Sell: Apellis Pharmaceuticals
MT
More news
News in other languages on APELLIS PHARMACEUTICALS, INC.
08/24Apellis Pharmaceuticals, Inc. Annonce des résultats à 24 mois montrant des effets accru..
08/18Vente d'initiés : Apellis Pharmaceuticals
08/16Vente d'initiés : Apellis Pharmaceuticals
08/15Vente d'initiés : Apellis Pharmaceuticals
08/08Apellis Pharmaceuticals réduit sa perte au deuxième trimestre et augmente son chiffre d..
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on APELLIS PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Products ETF - USD2.35%2.01%United_States
Invesco DWA Healthcare Momentum ETF - USD1.48%2.29%United_States
ETFs S&P Biotech ETF - Distributing - AUD1.31%2.97%-United_States
SPDR S&P Biotech ETF - USD1.14%0.99%United_States
Invesco Nasdaq Biotechnology ETF - USD0.61%2.33%-United_States
More ETFs positioned on APELLIS PHARMACEUTICALS, INC.
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 68,30 $
Average target price 78,12 $
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors